TR200200966T1 - Tüberkülöz ilaçlarının yeni farmasötik terkipleri ve hazırlanma prosesleri - Google Patents

Tüberkülöz ilaçlarının yeni farmasötik terkipleri ve hazırlanma prosesleri

Info

Publication number
TR200200966T1
TR200200966T1 TR2002/00966T TR200200966T TR200200966T1 TR 200200966 T1 TR200200966 T1 TR 200200966T1 TR 2002/00966 T TR2002/00966 T TR 2002/00966T TR 200200966 T TR200200966 T TR 200200966T TR 200200966 T1 TR200200966 T1 TR 200200966T1
Authority
TR
Turkey
Prior art keywords
isoniazid
pharmaceutical compositions
preparation processes
rifampicin
new pharmaceutical
Prior art date
Application number
TR2002/00966T
Other languages
English (en)
Inventor
Singh Amarjit
Jain Rajesh
Original Assignee
Panacea Biotec Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Limited filed Critical Panacea Biotec Limited
Publication of TR200200966T1 publication Critical patent/TR200200966T1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Oral kullanim için, Rifampicin ve/veya diger ilaçlarin biyokullanilabilirliginin artirildigi Rifampicin ve/veya Isoniazid içeren yeni bir tüberküloz ilaci farmasötik terkibi. Rifampicinin biyo kullanilabilirligi tercihen, Isoniazid varligiyla bozulmasi önlenerek artirilir. Rifampicin ve/veya Isoniazid, minimum miktarda ilacin pH 1-4 arasinda eriyecegi sekilde geç ve/veya uzun süreli salma formlarinda olabilir. Rifampicin ve/veya Isoniazidin geç salinmasi tercihen ilaçlarin,pH'a duyarli polimerler ile islenmesi yoluyla saglanir.
TR2002/00966T 2000-08-09 2001-04-10 Tüberkülöz ilaçlarının yeni farmasötik terkipleri ve hazırlanma prosesleri TR200200966T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN720DE2000 2000-08-09

Publications (1)

Publication Number Publication Date
TR200200966T1 true TR200200966T1 (tr) 2002-09-23

Family

ID=11097078

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00966T TR200200966T1 (tr) 2000-08-09 2001-04-10 Tüberkülöz ilaçlarının yeni farmasötik terkipleri ve hazırlanma prosesleri

Country Status (22)

Country Link
US (1) US7195769B2 (tr)
EP (1) EP1307199A2 (tr)
JP (2) JP4098620B2 (tr)
KR (1) KR100620404B1 (tr)
CN (1) CN1388758A (tr)
AU (1) AU778389C (tr)
BG (1) BG65848B1 (tr)
BR (1) BR0107147A (tr)
CA (1) CA2386725A1 (tr)
CZ (1) CZ20021319A3 (tr)
HU (1) HUP0203451A3 (tr)
IL (2) IL149030A0 (tr)
MX (1) MXPA02003596A (tr)
NO (1) NO322503B1 (tr)
NZ (1) NZ518216A (tr)
PL (1) PL355844A1 (tr)
RU (1) RU2240795C9 (tr)
TR (1) TR200200966T1 (tr)
UA (1) UA74164C2 (tr)
WO (1) WO2002011728A2 (tr)
YU (1) YU26102A (tr)
ZA (1) ZA200202637B (tr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7300670B2 (en) * 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
US20050084455A1 (en) * 2003-10-16 2005-04-21 Council Of Scientific & Industrial Research Inhalable biodegradable microparticles for target-specific drug delivery in tuberculosis and a process thereof
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
KR20070084325A (ko) * 2004-11-18 2007-08-24 브리스톨-마이어스 스큅 컴퍼니 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
CN1857220B (zh) * 2006-04-04 2010-10-06 济南康泉医药科技有限公司 一种抗结核病药物缓释剂
RU2327457C1 (ru) * 2007-06-26 2008-06-27 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Лекарственное средство на основе рифабутина, препарат противомикробного действия, содержащий наночастицы, и способ его получения
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
KR101197277B1 (ko) * 2009-02-05 2012-11-05 (주) 벡스코아 경구용 결핵의 치료용 또는 예방용 고형 제형
SG10201402158VA (en) * 2009-02-10 2014-07-30 Celgene Corp Methods Of Using And Compositions Comprising PDE4 Modulators For Treatment, Prevention And Management Of Tuberculosis
WO2011010214A1 (en) * 2009-07-23 2011-01-27 Cadila Pharmaceuticals Ltd. Pharmaceutical composition of rifampicin
WO2011012987A1 (en) * 2009-07-31 2011-02-03 Cadila Pharmaceuticals Ltd. Pharmaceutical composition of isoniazid
EA201201098A1 (ru) * 2010-04-07 2013-03-29 Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" Противотуберкулезный препарат на основе комплекса включения циклодекстрина с рифампицином и способ его получения
IT1400989B1 (it) * 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
US8470365B2 (en) 2010-07-29 2013-06-25 Taiwan Biotech Co., Ltd. Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom
TWI391134B (zh) * 2010-07-29 2013-04-01 Taiwan Biotech Co Ltd 製備抗結核病之組合的改良方法及由其製得之醫藥組合物
EA016410B1 (ru) * 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
CN102727496A (zh) * 2011-04-12 2012-10-17 上海双健现代药物技术咨询有限公司 一种复方抗结核药口服固体制剂及其制备方法
CN102228439B (zh) * 2011-06-21 2013-01-02 中国人民解放军第三0九医院 可注射利福霉素类抗生素凝胶微球及其制备方法
CN102552204B (zh) * 2011-12-30 2014-04-02 沈阳药科大学 复方抗结核包芯片及制备方法
CN102579447B (zh) * 2011-12-31 2014-10-15 沈阳药科大学 抗结核药物复方制剂的制备方法
MX365046B (es) 2012-05-01 2019-05-17 Althera Life Sciencies Llc Formulacion de tableta oral que consiste de una combinacion fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares.
WO2013166114A1 (en) * 2012-05-01 2013-11-07 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe
KR101301700B1 (ko) * 2012-11-14 2013-08-30 (주)비씨월드제약 용해도 및 안정성이 개선된 리팜피신을 포함하는 결핵 치료용 약학 조성물 및 이의 제조방법
CN105228617A (zh) * 2013-03-20 2016-01-06 印度生物技术部 抗耐药性细菌的抗菌化合物
CA2918828A1 (en) * 2013-07-26 2015-01-29 Sanofi Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation
WO2015011161A1 (en) * 2013-07-26 2015-01-29 Sanofi Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
RU2694056C2 (ru) 2013-07-26 2019-07-09 Санофи Противотуберкулезная стабильная фармацевтическая композиция в форме диспергируемой таблетки, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления
WO2016105238A1 (ru) * 2014-12-22 2016-06-30 Анатолий Викторович ЗАЗУЛЯ Изготовление двухслойных таблеток объединяющих механизмы повышения терапевтической эффективности и коррекции побочных действий
CN106619702A (zh) * 2016-12-07 2017-05-10 郑州郑先医药科技有限公司 一种治疗肺结核的药物
US11717519B2 (en) * 2017-04-21 2023-08-08 Washington University In St. Louis Use of fatty acid oxidation inhibitors as antimicrobials
US20200179273A1 (en) * 2017-06-06 2020-06-11 Merck Sharp & DohmeCorp Long-action implant for treatment of infectious diseases
CN108272766B (zh) * 2018-03-21 2020-07-07 江苏四环生物制药有限公司 一种甲钴胺分散迟释片及其制备方法
EP3578167A1 (en) 2018-06-04 2019-12-11 Universitat de Barcelona Suspension formulation for the treatment of tuberculosis
KR102304069B1 (ko) 2020-01-20 2021-09-23 인제대학교 산학협력단 항결핵제 치료 효과 증진용 조성물
CN112472702A (zh) * 2020-12-14 2021-03-12 卓和药业集团有限公司 一种治疗肺结核的药物组合物及其制备方法
CN114053229B (zh) * 2022-01-17 2022-04-22 山东国邦药业有限公司 一种盐酸沙拉沙星水溶性颗粒剂及其制备方法
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5817442B2 (ja) * 1977-04-25 1983-04-07 第一製薬株式会社 溶出の良いリフアンピシン固形製剤
GB2135879B (en) * 1983-03-07 1986-05-21 Ciba Geigy Ag Pharmaceutical preparations with uniform elution properties
JPH0498620A (ja) * 1990-08-15 1992-03-31 Nec Ibaraki Ltd 磁気記録媒体製造装置
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
EP0650728B1 (en) * 1993-10-29 2002-02-27 Council of Scientific and Industrial Research Pharmaceutical compositions containing piperine and an antituberculosis or antileprosydrug
IT1289883B1 (it) * 1996-10-09 1998-10-19 Lupin Lab Ltd Composizione farmaceutica antitubercolare e procedimento per la sua produzione
DE19710009A1 (de) * 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6264991B1 (en) * 1998-08-18 2001-07-24 Southern Research Institute Compositions and methods for treating intracellular infections
ES2179729B1 (es) * 2000-03-23 2003-12-16 Dreiman Lab Farmaceuticos S A Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.

Also Published As

Publication number Publication date
CA2386725A1 (en) 2002-02-14
HUP0203451A2 (hu) 2003-02-28
HUP0203451A3 (en) 2004-05-28
KR100620404B1 (ko) 2006-09-13
RU2240795C2 (ru) 2004-11-27
PL355844A1 (en) 2004-05-31
JP4098620B2 (ja) 2008-06-11
AU778389C (en) 2006-12-14
KR20020061602A (ko) 2002-07-24
BG106606A (bg) 2002-12-29
NZ518216A (en) 2004-11-26
NO322503B1 (no) 2006-10-16
AU778389B2 (en) 2004-12-02
JP2004505918A (ja) 2004-02-26
IL149030A0 (en) 2002-11-10
EP1307199A2 (en) 2003-05-07
CZ20021319A3 (cs) 2002-08-14
BR0107147A (pt) 2002-06-18
WO2002011728A3 (en) 2002-04-25
NO20021599D0 (no) 2002-04-04
BG65848B1 (bg) 2010-03-31
ZA200202637B (en) 2003-08-20
NO20021599L (no) 2002-06-10
IL149030A (en) 2007-06-17
US20030072800A1 (en) 2003-04-17
US7195769B2 (en) 2007-03-27
UA74164C2 (uk) 2005-11-15
RU2002115283A (ru) 2004-01-27
MXPA02003596A (es) 2003-10-14
JP2008056696A (ja) 2008-03-13
YU26102A (sh) 2004-12-31
AU5666101A (en) 2002-02-18
CN1388758A (zh) 2003-01-01
RU2240795C9 (ru) 2005-09-27
WO2002011728A2 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
TR200200966T1 (tr) Tüberkülöz ilaçlarının yeni farmasötik terkipleri ve hazırlanma prosesleri
TR200101353A2 (tr) Katı tümörlerin tedavisi için bir ilacın hazırlanmasında albümin ile kararlı hale getirilmiş paklitaksel kullanımı ve elde edilen ilaç
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
BR0014383A (pt) Composições de liberação controlada compreendendo nimesulida
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
TR200002953T2 (tr) İki halkalı hidroksamik asit türevleri
TR200901979T2 (tr) Antikolinerjik etkili bileşik ve ?-mimetikler bazında yeni ilaç bileşimleri.
EE04850B1 (et) Pürimidiini derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud HIV nakkuse raviks, ühend, seda sisaldav farmatseutiline kompositsioon, meetod ühendi ja kompositsiooni valmistamiseks ning kombineeritud preparaat kasutamiseks HIV nakku
TR199802273T2 (tr) Fibrotik lezyonlarin onarilmasi ve önlenmesi.
DE69922676D1 (de) N-aralkylaminotetraline als neuropeptid-y-y5-rezeptorliganden
EE200200202A (et) Uudsed tritsüklilised ühendid, nende saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud HIV-nakkuse raviks, ning neid sisaldav farmatseutiline kompositsioon
NO20073405L (no) Farmasoytisk utforming inneholdende en frigjoringshastighetskontrollerende sammensetning
TR200000223T2 (tr) XA faktörünü engelleyen heterosiklik türevler
TR200103153T2 (tr) Yeni bileşimler
ATE247953T1 (de) Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
PT1147105E (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente activo e sua utilizacao no tratamento de doencas vasculares
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
ATE326451T1 (de) Chinazolin derivate und therapeutische verwendungen davon
TR199800165T1 (tr) (R)-5-bromo-n-(1-etil-4-metil hekzahidro-1h-1,4-diazepin-6-il)-2-metoksi-6- metilamino-3-piridinkarboksamid, bunu hazirlamaya mahsus yöntem ve bu bilesigi ihtiva eden farmasötik terkip.
TR200103144T2 (tr) Yeni bileşikler
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
DE50000864D1 (de) Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit
TR200103090T2 (tr) Integrın reseptör antagonistleri
TR200102306T2 (tr) Faktör Xa önleyici olarak heterosiklik türevler.
EE9600202A (et) Toimeaine pärsitud vabanemisega karbamasepiini ravimvorm